<html><body><p><h1>A Randomized Trial of Novel Drug X in Patients with Hypertension</p>
<p><strong>Protocol Number:<strong> RCT-DEMO-2024-001
<strong>Principal Investigator:<strong> Dr. Sarah Wilson, MD, PhD
<strong>Study Phase:<strong> Phase III
<strong>Version:<strong> 1.0
<strong>Date:<strong> February 04, 2026</p>
<p>#<h1>Protocol Synopsis</p>
<p><strong>Background:<strong> This randomized controlled trial is designed to evaluate the efficacy and safety of the investigational treatment.</p>
<p><strong>Primary Objective:<strong> To evaluate the efficacy of Drug X in reducing systolic blood pressure compared to placebo</p>
<p><strong>Secondary Objectives:<strong> To assess safety, tolerability, and quality of life improvements</p>
<p><strong>Study Design:<strong> Randomized, double-blind, placebo-controlled, parallel-group study</p>
<p><strong>Study Population:<strong> Adults aged 18-75 with essential hypertension</p>
<p><strong>Sample Size:<strong> 400 participants</p>
<p>#<h1>Study Objectives</p>
<p>##<h1>Primary Objective
To evaluate the efficacy of Drug X in reducing systolic blood pressure compared to placebo</p>
<p>##<h1>Secondary Objectives
To assess safety, tolerability, and quality of life improvements</p>
<p>#<h1>Study Design</p>
<p><strong>Design Type:<strong> Parallel Group
<strong>Randomization:<strong> Central randomization with stratification
<strong>Blinding:<strong> Double-blind (participant and investigator)
<strong>Treatment Duration:<strong> 12 weeks</p>
<p>##<h1>Treatment Groups
- <strong>Group A:<strong> Investigational Drug
- <strong>Group B:<strong> Placebo</p>
<p>#<h1>Statistical Considerations</p>
<p><strong>Primary Endpoint:<strong> Change from baseline in primary efficacy measure</p>
<p><strong>Sample Size Calculation:<strong>
- Target Sample Size: 400 participants
- Power: 90%
- Alpha Level: 0.05
- Expected Effect Size: 0.5</p>
<p><strong>Statistical Analysis:<strong> Mixed model repeated measures (MMRM) analysis</p>
<p>#<h1>Study Procedures</p>
<p>##<h1>Screening Period
Participants will undergo comprehensive screening to determine eligibility.</p>
<p>##<h1>Treatment Period  
Eligible participants will be randomized to receive either investigational treatment or placebo.</p>
<p>##<h1>Follow-up Period
Safety follow-up will continue for 30 days after last dose.</p>
<p>---</p>
<p>*This protocol was generated using the Enhanced Protocol Generation System with PHI compliance and regulatory framework support.*</p>
<p><strong>Generated:<strong> 2026-02-04 04:26:54
<strong>Template:<strong> RCT Basic v1.0
<strong>Compliance:<strong> HIPAA, ICH-GCP
</p></body></html>